Ophthotech Corp (NASDAQ:OPHT), Director Nicholas Galakatos unloaded 144,976 shares of the company’s stock on the open market in a transaction dated Monday, June 16th. The stock was sold at an average price of $44.17, for a total value of $6,403,589.92. Ophthotech Corp (NASDAQ:OPHT), weekly performance is -3.81%. On last trading day company shares ended up $40.67. Analysts mean target price for the company is $63.25. Ophthotech Corp (NASDAQ:OPHT), distance from 50-day simple moving average (SMA50) is 8.86%.
Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), were the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 20,716,430 shares, a growth of 9.8% from the March 31st total of 18,875,693 shares,AnalystRatingsNetwork reports. Based on an average daily volume of 1,554,211 shares, the days-to-cover ratio is presently 13.3 days. Currently, 35.4% of the shares of the company are short sold. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), fell 5.37% in last trading session and ended the day on $4.05. ZIOP, return on assets is -102.80%. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), quarterly performance is -80.16%.
Intercept Pharmaceuticals Inc (NASDAQ:ICPT), CMO David Shapiro unloaded 4,000 shares of the company’s stock on the open market in a transaction dated Monday, June 16th. The stock was sold at an average price of $278.15, for a total value of $1,112,600.00. Following the completion of the transaction, the chief marketing officer now directly owns 14,440 shares in the company, valued at approximately $4,016,486. Intercept Pharmaceuticals Inc (NASDAQ:ICPT), shares moved down 5.61% in last trading session and was closed at $239.42, while trading in range of $237.50 – 258.00. Intercept Pharmaceuticals Inc (NASDAQ:ICPT), year to date (YTD) performance is 250.64%.
On June 18, 2014, EnteroMedics Inc (NASDAQ:ETRM)’s shares jumped about 37 percent in premarket trading, a day after an advisory panel to the U.S. Food and Drug Administration voted in favor of the company’s device to treat obesity. EnteroMedics Inc (NASDAQ:ETRM), ended the last trading day at $1.53. Company weekly volatility is calculated as 6.36% and price to cash ratio as 4.21. EnteroMedics Inc (NASDAQ:ETRM), showed a negative weekly performance of 14.53%.
Biostar Pharmaceuticals Inc (NASDAQ:BSPM), net profit margin is 2.00% and weekly performance is -6.85%. On last trading day company shares ended up $1.36. Analysts mean target price for the company is $7.00. Biostar Pharmaceuticals Inc (NASDAQ:BSPM), distance from 50-day simple moving average (SMA50) is -10.36%.